Lai, Sunny Y.Richardson, Noah H.Tran, MyaHanna, Nasser H.Shields, Misty D.2024-04-252024-04-252024-04Lai, S. Y., Richardson, N. H., Tran, M., Hanna, N. H., & Shields, M. D. (2024). Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated with Osimertinib: A Case Report. JTO Clinical and Research Reports, 100652. https://doi.org/10.1016/j.jtocrr.2024.100652https://hdl.handle.net/1805/40251EGFR mutations are among the most common driver mutations in lung adenocarcinoma. Rare alterations, such as the EGFR-RAD51 fusion, respond to treatment with EGFR tyrosine kinase inhibitors but can be missed by limited genomic sequencing panels. Here, we report a case of metastatic lung adenocarcinoma in a never-smoker patient who initially did not have a targetable alteration identified on two different sequencing panels. The initial response to combination chemoimmunotherapy was short-lived. A rare EGFR-RAD51 fusion was then identified using a more in-depth sequencing panel. The patient experienced a dramatic and durable response to osimertinib. This case highlights the rarity of EGFR-RAD51 fusions, the efficacy of EGFR tyrosine kinase inhibitors, and the importance of a thorough search for targetable alterations in never-smokers with lung adenocarcinoma.en-USPublisher PolicyNon–small cell lung cancerEGFR fusionTKICase reportNGSOsimertinibArticle